Applying Rituximab During the Conditioning Regimen Prevents Epstein–Barr Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplant in a Children’s Cohort: A Retrospective Case–Control Study

Applying Rituximab During the Conditioning Regimen Prevents Epstein–Barr Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplant in a Children’s Cohort: A Retrospective Case–Control Study

Abstract Introduction Since hematopoietic stem cell transplant (HSCT) is an important therapy for malignant and non-malignant pediatric diseases, improving transplant-related mortality remains a challenge. Currently, rituximab, a monoclonal antibody of anti-CD20, is widely used for several post-HSCT...

Full description

Bibliographic Details
Main Authors: Yongsheng Ruan, Libai Chen, Tingting Luo, Danfeng Xie, Wei Cao, Xuan Liu, Qiujun Liu, Yuhua Xiao, Cuiling Wu, Jianyun Wen, Juan Li, Jiangnan Meng, Xuedong Wu, Xiaoqin Feng
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-07-01
Series:Infectious Diseases and Therapy
Subjects:
Rituximab
B cell
Hematopoietic stem cell transplant
Epstein–Barr virus
Children
Online Access:https://doi.org/10.1007/s40121-023-00841-x

Internet

https://doi.org/10.1007/s40121-023-00841-x

Similar Items